The revenue miss is largely structural (one-time license fee lapsing), but the net loss swing and reliance on a single Phase 3 readout create binary risk. Monitor 4WARD enrollment updates and any Norgine milestone announcements. Cash runway through 2028 removes near-term financing risk.
Price Chart
Executive Summary
X4 Pharmaceuticals reported Q1 2026 revenue of $2.7M (vs $3.2M consensus) and GAAP EPS of -$0.16 (vs consensus -$0.20, a beat of 20%). The revenue miss was driven by the absence of the prior-year $27.9M Norgine license fee, while product revenue grew to $2.5M from $0.9M. The company reiterated its Phase 3 4WARD trial enrollment timeline and cash runway through 2028, but the revenue decline and net loss swing from prior-year profit are material negatives.
Key Financial Metrics
Key Facts
- Q1 2026 total revenue $2.7M vs $28.8M in Q1 2025, a 90.6% decline due to absence of $27.9M Norgine license revenue
- GAAP net loss of $(20.2)M or $(0.16)/share vs net income of $0.3M or $0.04/share in Q1 2025
- Product revenue (XOLREMDI) grew to $2.5M from $0.9M year-over-year, a 162% increase
- Cash position $233.7M as of March 31, 2026, providing runway through 2028
- European Commission approved XOLREMDI for WHIM syndrome; Norgine to lead commercialization with up to €226M in milestones plus double-digit royalties
- Phase 3 4WARD chronic neutropenia trial on track to complete enrollment by end of Q3 2026
Financial Impact
Revenue decline of $26.1M YoY driven by one-time license fee; net loss swing of $20.5M; product revenue growth of $1.5M partially offsetting
Risk Factors
- Phase 3 4WARD trial failure would eliminate pipeline value and likely require restructuring
- Product revenue from XOLREMDI remains small ($2.5M/quarter) and may not offset operating burn
- Dependence on Norgine for European commercialization; milestone timing uncertain
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288685 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 8-K | $2.91 | awaiting T+20 | — | $3.25 (+11.68%) |
Oct 7, 2026 20d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.25 (+15.66%) |
Oct 1, 2026 25d ago | 144 | $2.83 | awaiting T+20 | — | $3.25 (+14.84%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.25 (−5.25%) |
Sep 8, 2026 7w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.25 (−7.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.25 (−22.99%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.25 (−24.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.25 (−11.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers